Excellent Overall Survival in Head & Neck Cancer Patients
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Immutep Ltd reports excellent overall survival results for head and neck cancer patients treated with its immunotherapy Efti in combination with KEYTRUDA® (pembrolizumab). Immutep plans to meet with the FDA to discuss potential approval pathways for this treatment, highlighting the high unmet medical need in this patient population.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Immutep
- Immutep Quarterly Activities Report Q3 FY25
- Immutep to Participate in Upcoming Investor Conferences
- First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
- First patient dosed in phase 3 TACTI-004 lung cancer trial
- Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
Later from Immutep
- Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
- High Response Rates achieved in Lung Cancer in INSIGHT-003
- Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
- Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial
- Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep